Theratechnologies Inc (TSE:TH) – Analysts at National Bank Financial issued their Q4 2018 earnings per share estimates for shares of Theratechnologies in a note issued to investors on Wednesday, February 20th. National Bank Financial analyst E. Leno anticipates that the company will post earnings per share of $0.01 for the quarter. National Bank Financial currently has a “Outperform” rating and a $12.75 price objective on the stock.
Theratechnologies stock opened at C$8.34 on Friday. The company has a debt-to-equity ratio of 137.57, a current ratio of 2.89 and a quick ratio of 2.40. The firm has a market cap of $607.54 million and a P/E ratio of -70.68. Theratechnologies has a one year low of C$6.72 and a one year high of C$14.75.
Theratechnologies Company Profile
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. The company's lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada.
Further Reading: What are the Different Types of Leveraged Buyouts?
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.